Johannes Fruehauf, MD PhD General Partner
Johannes Fruehauf (MD PhD) is General Partner of BioInnovation Capital. Johannes is a physician and serial biotech entrepreneur. He is the Executive Director
and President of LabCentral and is the Founder and CEO of Cambridge BioLabs (CBL), a contract research facility servicing startup and virtual companies in Kendall Square.
Johannes, Eric Linsley, Susie Harborth and Peter Parker first teamed up to create Cequent Pharmaceuticals in 2006 based on Johannes’ research work
at Beth Israel Deaconess Medical Center in Boston. At BioInnovation Capital, Johannes sources,
diligences, and leads new investment transactions. Through his role at LabCentral and Cambridge BioLabs, and his connections at Harvard, MassChallenge, MassBio,
and MIT, Johannes is currently in touch with a preponderance of the early stage life sciences investment
opportunities in the Boston/Cambridge ecosystem.
Johannes has a long track record of building successful research organizations. He is a co-founder at ViThera Pharmaceuticals and Deltix and served as a consultant to a number of biotechnology companies and non-profits,
including Aura Biosciences, Izon,
Advirna, and Unitio. Johannes is the author
of over 30 peer-reviewed publications and is named inventor on 9 patents. He earned his medical degree at the University of Frankfurt and his PhD at the University of Heidelberg (Germany).